Prof. Azab earned a Pharmacy degree (2000), MSc in Medicinal Chemistry (2003) and a Ph.D. in Pharmaceutical Sciences (2007) from The Hebrew University of Jerusalem, and completed post-doctoral training focusing on biology of hematologic malignancies at Harvard Medical School/Dana-Farber Cancer Institute in 2012. Prof. Azab has co-authored over 80 peer-reviewed papers and 10 patents, and mentored over 40 Post-doctoral, PhD, MSc and Undergraduate Students.
The research in Prof. Azab’s Lab has a multidisciplinary translational approach involving cancer biology, immunotherapy, tissue engineering, and drug delivery. He has special interest in tumor biomarkers, tumor microenvironment, drug resistance, and metastasis in hematologic malignancies, particularly in Multiple Myeloma. He also focuses on development of ex vivo 3D tissue engineered cancer models for drug development and personalized medicine. Moreover, he specializes in development of drug delivery systems to improve the specificity and efficacy of cancer treatment: from nanoscale (targeted polymeric nanoparticles and liposomes) up to biodegradable-biocompatible natural and synthetic implant devices for controlled release of chemo and radiotherapy.